Coherus Oncology, Inc.

CHRS Healthcare Biotechnology

In the quarter to June 2026, revenue grew 39.5%, EPS fell 105.1%, free cash flow fell 33.2% and total debt rose 1.03%, each against the same quarter a year earlier.

1.00 0.07 −6.54%
Market cap
$165.3M
P/E
0.0×
Fwd P/E
−1.4×
Dividend yield
—
F-score
6/9
Altman Z
−8.83
Beneish M
−3.44
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Piotroski F-Score

+8 more TTM periods

4 6 5 3
ROE
(155,671.52%) (473.47%) (355.31%) (146.27%)
ROA
30.34% 47.54% 58.47% (41.90%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
171.64% 248.32% 249.03% (223.41%)
Average Days of Receivables
2,460.67 159.41 175.25 102.13
Free Cash Flow per Share
(0.78) (1.18) (1.25) (1.20)
Free Cash Flow
(90.19) (138.51) (170.57) (186.03)
Other line items

Show all line items

Columns are period end dates